查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600752

藥物發現市場：按藥物類型、技術、治療領域和最終用戶分類 - 2025-2030 年全球預測

Drug Discovery Market by Drug Type (Biologic Drugs, Small Molecule Drugs), Technology (Bioanalytical Instruments, Biochips, Bioinformatics), Therapeutic Area, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年藥物發現市值為623.8億美元，預計到2024年將達到711.2億美元，複合年成長率為14.10%，到2030年將達到1571.3億美元。

藥物發現市場涉及新治療藥物的鑑定和開拓。在臨床前測試之前發現並最佳化新藥的潛力是藥物研究的關鍵階段。隨著新出現的健康威脅、慢性病和抗生素抗藥性病原體的刺激，對新藥的需求不斷增加，這個市場至關重要。藥物發現的應用範圍從生物技術和製藥公司到研究機構和學術機構，重點關注腫瘤學、神經病學和感染疾病等領域。影響成長的關鍵因素包括人工智慧和機器學習的進步，簡化了發現過程，製藥巨頭增加了研發投資，以及提高了創新和效率。除了個人化醫療和生技藥品的市場開拓之外，擴大學術機構和生物企業之間的合作的機會也已經成熟，這可以加速突破並縮短上市時間。策略夥伴關係和授權協議也為公司利用彼此的優勢提供了途徑。然而，市場開拓面臨藥物開發成本高、週期長、監管要求嚴格以及臨床試驗期間可能出現高失敗率等挑戰。智慧財產權問題和學名藥的競爭也是問題。資料存取和整合的限制使研究工作更加複雜。預計將成長的技術創新包括使用 CRISPR 和其他基因組技術，以及整合巨量資料分析以更有效地預測藥物交互作用和功效。市場是競爭性的但也是協作性的，並且有開放創新以及資源和知識共用的趨勢。尋求發展的公司應專注於早期夥伴關係關係，並利用技術進步來降低風險並最佳化藥物發現計劃的資源分配。

主要市場統計
基準年[2023] 623.8億美元
預測年份 [2024] 711.2億美元
預測年份 [2030] 1571.3億美元
複合年成長率（%） 14.10%

市場動態：揭示快速發展的藥物發現市場的關鍵市場洞察

供需的動態交互作用正在改變藥物發現市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 醫藥及生技製藥產業研發費用增加
    • 管理臨床前研究期間產生的大規模資料的需求日益增加
    • 政府對藥物發現平台開發的有利支持
  • 市場限制因素
    • 藥物發現和開發需要巨額資金
  • 市場機會
    • 建立公司之間的合作以擴大藥物發現能力
    • 藥物發現的技術進步與創新
    • 使用 AI 雲實現藥物發現合理化和自動化的方法
  • 市場挑戰
    • 關於在藥物發現中使用動物的嚴格規範

波特的五力：駕馭藥物發現市場的策略工具

波特的五力框架是了解藥物發現市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解藥物發現市場的外部影響

外部宏觀環境因素在塑造藥物發現市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解藥物發現市場的競爭狀況

對藥物發現市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣藥物發現市場供應商的績效評估

FPNV 定位矩陣是評估藥物發現市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪藥物發現市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，藥物發現市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 醫藥及生技製藥產業研發費用增加
      • 管理臨床前研究過程中產生的大量資料的需求日益成長。
      • 政府對藥物發現平台開發的有利支持
    • 抑制因素
      • 藥物發現和開發需要大量資金
    • 機會
      • 公司之間的合作誕生，擴大了藥物發現能力
      • 藥物發現的技術進步與創新
      • 使用 AI 雲創建藥物發現的簡化自動化方法
    • 任務
      • 在藥物發現中使用動物的嚴格標準
  • 市場區隔分析
    • 藥物類型：對品牌藥和非專利藥小分子藥物的需求不斷增加
    • 技術：擴大生物分析儀器的使用和早期高通量篩檢
    • 治療領域：腫瘤療法開發中對藥物發現的需求不斷增加
    • 最終用戶：製藥和生物技術公司更多地利用藥物發現來開發新的和改進的藥物
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按藥物類型分類的藥物發現市場

  • 生物製藥
  • 小分子藥物

第7章藥物發現市場：依技術分類

  • 生物分析設備
  • 生物晶片
  • 生物資訊學
  • 組合化學
  • 高通量篩檢
  • 奈米科技
  • 藥物基因組學

第8章按治療領域分類的藥物發現市場

  • 心血管疾病
  • 消化系統疾病
  • 感染疾病及免疫系統疾病
  • 神經病學
  • 腫瘤學

第9章藥物發現市場：依最終使用者分類

  • 學術研究機構
  • 合約調查機構
  • 製藥公司

第10章美洲藥物發現市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太藥物發現市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的藥物發現市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Exscientia PLC 與 AWS 合作，利用人工智慧和雲端技術加速藥物發現並降低成本。
    • Enzene Biosciences推出新藥發現部門並提供全面服務
    • 埃默里大學新藥中心利用先進技術加速藥物發現，以改善病患治療結果和合作研究。
    • 奧勒岡 Therapeutics 與 Lantern Pharma 合作，利用抗藥性癌症的 RADR AI 平台推進 XCE853 的開發
    • Xaira Therapeutics 已籌集超過 10 億美元資金，旨在透過創新的機器學習模式徹底改變人工智慧主導的藥物發現。
    • bioXcelerate 發布 PleioGraph AI 工具，徹底改變藥物發現、降低成本並加速治療速度 100 倍
    • 加州大學柏克萊分校的分子治療舉措(MTI) 旨在透過跨學科合作加速神經、代謝和癌症疾病突破性治療方法的發展。
    • 丹麥量子計算公司 Kvantify 推出 Kvantify Koffee，透過快速篩檢、節省成本和麵向未來的技術整合徹底改變藥物發現
    • 華盛頓大學和 Deerfield Management 合作成立 VeritaScience，投資 1.3 億美元推進藥物發現和開發
    • 耗資 5 億美元的 Arena BioWorks 在肯德爾廣場開業，旨在將創新藥物推向市場並加速藥物發現。
    • Evommune 和 Accutar Biotechnology 宣布開展人工智慧藥物發現合作
    • IGC Pharma 簽署協議，將人工智慧解決方案引入藥物發現
    • 筑波大學與Astellas來製藥結成策略聯盟
    • Sosei 與 Farm Enable 合作開發新型神經藥物
    • 諾和諾德和 Evotech 推出轉換加速器
    • Genesis 籌集了 2 億美元用於藥物發現領域的人工智慧研究
  • 戰略分析和建議
    • 英偉達公司
    • F.霍夫曼羅氏有限公司
    • 埃森蒂亞公司
    • 阿爾肯實驗室有限公司

公司名單

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Alacrita Holdings Limited
  • Alkem Laboratories Ltd
  • Amgen Inc.
  • Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
  • Astrazeneca PLC
  • Atomwise, Inc.
  • BenevolentAI
  • Bio-Rad Laboratories, Inc.
  • BioSymetrics Inc.
  • Charles River Laboratories International, Inc.
  • Chembridge Corporation
  • Cloud Pharmaceuticals, Inc.
  • Dalriada Drug Discovery
  • Deciphera Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Evotec SE
  • Exscientia PLC
  • F. Hoffmann-La Roche Ltd.
  • GENFIT SA
  • Incyte Corporation
  • International Business Machines Corporation
  • Intra-Cellular Therapies Inc.
  • Kvantify
  • Lantern Pharma Inc.
  • Merck KGaA
  • Microsoft Corporation
  • NVIDIA Corporation
  • PerkinElmer, Inc.
  • Pharmacelera SL
  • Piramal Group
  • Recursion Pharmaceuticals, Inc.
  • Sanofi SA
  • Schrodinger, Inc.
  • Shimadzu Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-434CCDA0516F

The Drug Discovery Market was valued at USD 62.38 billion in 2023, expected to reach USD 71.12 billion in 2024, and is projected to grow at a CAGR of 14.10%, to USD 157.13 billion by 2030.

The drug discovery market involves the identification and development of new therapeutic drugs. It's a critical phase in pharmaceutical research where potential new medications are discovered and optimized before preclinical studies. This market is essential due to the ever-increasing demand for novel medications, spurred by emerging health threats, chronic diseases, and antibiotic-resistant pathogens. The application of drug discovery spans from biotechnology and pharmaceutical companies to research facilities and academic institutions, focusing on areas like oncology, neurology, infectious diseases, and more. Key factors influencing growth include advances in AI and machine learning, which streamline the discovery process, and increased investments in R&D by pharmaceutical giants, driving innovation and efficiency. Opportunities are ripe in personalized medicine and the development of biologics, as well as expanding collaborations between academic institutions and biotech firms, which can accelerate breakthroughs and reduce time-to-market. Strategic partnerships and licensing agreements also provide pathways for companies to leverage each other's strengths. However, the market faces challenges including high costs and lengthy timelines associated with drug development, stringent regulatory requirements, and the potential for high failure rates during clinical trials. Intellectual property issues and competition from generics also pose challenges. Limitations in data access and integration further complicate research efforts. Innovations poised for growth include the utilization of CRISPR and other genomic technologies, as well as the integration of big data analytics to predict drug interactions and efficacy more efficiently. The nature of the market is highly competitive but collaborative, with a trend toward open innovation and sharing of resources and knowledge. Companies aiming for growth should focus on early-stage partnerships and harnessing technological advancements to mitigate risks and optimize resource allocation for drug discovery projects.

KEY MARKET STATISTICS
Base Year [2023] USD 62.38 billion
Estimated Year [2024] USD 71.12 billion
Forecast Year [2030] USD 157.13 billion
CAGR (%) 14.10%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Drug Discovery Market

The Drug Discovery Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising R&D expenditure in the pharmaceutical & biopharmaceutical industry
    • Increasing need to manage large data generated during preclinical studies
    • Favorable government support for the development of drug discovery platforms
  • Market Restraints
    • Requirement of extensive capital for drug discovery and development
  • Market Opportunities
    • Emerging collaborations among companies to expand their drug discovery capabilities
    • Technological advancements and innovations in drug discovery
    • Use of AI cloud to create a streamlined and automated approach in drug discovery
  • Market Challenges
    • Stringent norms for animal usage in drug discovery

Porter's Five Forces: A Strategic Tool for Navigating the Drug Discovery Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Drug Discovery Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Drug Discovery Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Drug Discovery Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Drug Discovery Market

A detailed market share analysis in the Drug Discovery Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Drug Discovery Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Drug Discovery Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Drug Discovery Market

A strategic analysis of the Drug Discovery Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Alacrita Holdings Limited, Alkem Laboratories Ltd, Amgen Inc., Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd., Astrazeneca PLC, Atomwise, Inc., BenevolentAI, Bio-Rad Laboratories, Inc., BioSymetrics Inc., Charles River Laboratories International, Inc., Chembridge Corporation, Cloud Pharmaceuticals, Inc., Dalriada Drug Discovery, Deciphera Pharmaceuticals, Inc., Eli Lilly and Company, Evotec SE, Exscientia PLC, F. Hoffmann-La Roche Ltd., GENFIT SA, Incyte Corporation, International Business Machines Corporation, Intra-Cellular Therapies Inc., Kvantify, Lantern Pharma Inc., Merck KGaA, Microsoft Corporation, NVIDIA Corporation, PerkinElmer, Inc., Pharmacelera SL, Piramal Group, Recursion Pharmaceuticals, Inc., Sanofi S.A, Schrodinger, Inc., Shimadzu Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Drug Discovery Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Biologic Drugs and Small Molecule Drugs.
  • Based on Technology, market is studied across Bioanalytical Instruments, Biochips, Bioinformatics, Combinatorial Chemistry, High Throughput Screening, Nanotechnology, and Pharmacogenomics.
  • Based on Therapeutic Area, market is studied across Cardiovascular Disease, Digestive System Diseases, Infectious & Immune system Diseases, Neurology, and Oncology.
  • Based on End User, market is studied across Academics & Research Institutes, Contract Research Organizations, and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Georgia, Illinois, Indiana, Michigan, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising R&D expenditure in the pharmaceutical & biopharmaceutical industry
      • 5.1.1.2. Increasing need to manage large data generated during preclinical studies
      • 5.1.1.3. Favorable government support for the development of drug discovery platforms
    • 5.1.2. Restraints
      • 5.1.2.1. Requirement of extensive capital for drug discovery and development
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging collaborations among companies to expand their drug discovery capabilities
      • 5.1.3.2. Technological advancements and innovations in drug discovery
      • 5.1.3.3. Use of AI cloud to create a streamlined and automated approach in drug discovery
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent norms for animal usage in drug discovery
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Growing need for small molecule drugs with branded and generic products
    • 5.2.2. Technology: Growing utilization of bioanalytical instruments and high throughput screening for initial drug discovery phases
    • 5.2.3. Therapeutic Area: Increasing need of drug discovery for the development of oncology drugs
    • 5.2.4. End User: Growing drug discovery use across pharmaceutical and biotechnology companies for developing new and improved drugs
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Drug Discovery Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Biologic Drugs
  • 6.3. Small Molecule Drugs

7. Drug Discovery Market, by Technology

  • 7.1. Introduction
  • 7.2. Bioanalytical Instruments
  • 7.3. Biochips
  • 7.4. Bioinformatics
  • 7.5. Combinatorial Chemistry
  • 7.6. High Throughput Screening
  • 7.7. Nanotechnology
  • 7.8. Pharmacogenomics

8. Drug Discovery Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiovascular Disease
  • 8.3. Digestive System Diseases
  • 8.4. Infectious & Immune system Diseases
  • 8.5. Neurology
  • 8.6. Oncology

9. Drug Discovery Market, by End User

  • 9.1. Introduction
  • 9.2. Academics & Research Institutes
  • 9.3. Contract Research Organizations
  • 9.4. Pharmaceutical Companies

10. Americas Drug Discovery Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Drug Discovery Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Drug Discovery Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Exscientia PLC partners with AWS to harness AI and cloud technology for accelerating drug discovery and reducing costs
    • 13.3.2. Enzene Biosciences launches new drug discovery division offering integrated services
    • 13.3.3. Emory University's Center for New Medicines accelerates drug discovery with advanced technology for improved patient outcomes and collaborative research.
    • 13.3.4. Oregon Therapeutics partners with Lantern Pharma to advance XCE853 development using RADR AI platform, targeting drug-resistant cancers
    • 13.3.5. Xaira Therapeutics launches with over USD 1 billion funding to revolutionize AI-driven drug discovery with innovative machine learning models
    • 13.3.6. bioXcelerate launches PleioGraph AI tool to revolutionize drug discovery, cutting costs and accelerating treatments by 100x
    • 13.3.7. UC Berkeley's Molecular Therapeutics Initiative (MTI) aims to accelerate breakthrough treatments for neurological, metabolic diseases, and cancer through interdisciplinary collaboration
    • 13.3.8. Danish quantum computing firm Kvantify unveils Kvantify Koffee to revolutionize drug discovery with expedited screening, cost reduction, and future-proof technology integration
    • 13.3.9. Washington University and Deerfield Management partner to launch VeritaScience, committing USD 130 million to advance drug discovery and development
    • 13.3.10. Arena BioWorks opens in Kendall Square with USD 500 million to accelerate drug discovery and market innovative medicines.
    • 13.3.11. Evommune and Accutar Biotechnology announce AI drug discovery collaboration
    • 13.3.12. IGC Pharma signs agreement to adopt AI solutions into drug discovery
    • 13.3.13. University of Tsukuba and Astellas Pharma Inc. confirm a strategic partnership
    • 13.3.14. Sosei and PharmEnable collaborate on another neurological drug
    • 13.3.15. Novo Nordisk and Evotec launch translational drug discovery accelerator
    • 13.3.16. Genesis raises USD 200 million for AI drug discovery research
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. NVIDIA Corporation
    • 13.4.2. F. Hoffmann-La Roche Ltd.
    • 13.4.3. Exscientia PLC
    • 13.4.4. Alkem Laboratories Ltd

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. Alacrita Holdings Limited
  • 4. Alkem Laboratories Ltd
  • 5. Amgen Inc.
  • 6. Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
  • 7. Astrazeneca PLC
  • 8. Atomwise, Inc.
  • 9. BenevolentAI
  • 10. Bio-Rad Laboratories, Inc.
  • 11. BioSymetrics Inc.
  • 12. Charles River Laboratories International, Inc.
  • 13. Chembridge Corporation
  • 14. Cloud Pharmaceuticals, Inc.
  • 15. Dalriada Drug Discovery
  • 16. Deciphera Pharmaceuticals, Inc.
  • 17. Eli Lilly and Company
  • 18. Evotec SE
  • 19. Exscientia PLC
  • 20. F. Hoffmann-La Roche Ltd.
  • 21. GENFIT SA
  • 22. Incyte Corporation
  • 23. International Business Machines Corporation
  • 24. Intra-Cellular Therapies Inc.
  • 25. Kvantify
  • 26. Lantern Pharma Inc.
  • 27. Merck KGaA
  • 28. Microsoft Corporation
  • 29. NVIDIA Corporation
  • 30. PerkinElmer, Inc.
  • 31. Pharmacelera SL
  • 32. Piramal Group
  • 33. Recursion Pharmaceuticals, Inc.
  • 34. Sanofi S.A
  • 35. Schrodinger, Inc.
  • 36. Shimadzu Corporation
  • 37. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. DRUG DISCOVERY MARKET RESEARCH PROCESS
  • FIGURE 2. DRUG DISCOVERY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DRUG DISCOVERY MARKET DYNAMICS
  • TABLE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023